Paysign Accelerates Growth with Ahead-of-Schedule Transition of 123 Plasma Donation Centers
We delivered a seamless experience for center staff, leadership teams and donors—without disruption—setting a new benchmark for speed and precision in the industry.
Share
The onboarding of 123 centers was completed in just one week – significantly ahead of schedule – demonstrating Paysign's operational agility, platform scalability and executional discipline.
'Successfully transitioning this volume of centers in a single week is a testament to the strength of our platform, the rigor of our processes and the exceptional capabilities of our team,' said Mark Newcomer, President and CEO of Paysign. 'We delivered a seamless experience for center staff, leadership teams and donors—without disruption—setting a new benchmark for speed and precision in the industry. The addition of these centers represents a pivotal return to revenue growth for this business unit. This, combined with the continuing exceptional growth of our patient affordability business, gives us great confidence in Paysign's forward momentum.'
This achievement reinforces Paysign's strategic value to plasma collection organizations seeking reliable, scalable and compliant payment solutions. It also underscores the company's continued momentum in the healthcare financial services sector and its ability to capitalize on growth opportunities with speed and efficiency.
Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.
About Paysign
Paysign, Inc. is a leading provider of prepaid card programs, comprehensive patient affordability offerings, financial technology products and integrated payment processing designed for businesses, consumers and government institutions. Incorporated in 1995 and headquartered in southern Nevada, the company creates customized, innovative payment solutions for clients across all industries, including pharmaceutical, healthcare, hospitality, and retail. Built on the foundation of a reliable payments platform, Paysign's end-to-end technologies securely enable digital payout solutions and facilitate the distribution of funds for donor compensation, copay assistance, customer incentives, employee rewards, travel expenses, per diem, reimbursements, rebates, and countless other exchanges of value. Paysign's solutions lower costs, streamline operations and improve customer, employee and partner loyalty. To learn more, visit paysign.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Why TeraWulf Stock Is Skyrocketing Today
Key Points TeraWulf inked a multiyear, multibillion-dollar agreement to provide up to 200 megawatts of compute power to an AI cloud provider. The deal will be backed by Google in exchange for a potential 8% stake in TeraWulf. 10 stocks we like better than TeraWulf › Shares of TeraWulf (NASDAQ: WULF) are flying on Thursday, up 44.1% as of 1:09 p.m. ET. The jump comes as the S&P 500 and Nasdaq Composite were down slightly. TeraWulf, a Bitcoin miner and high-performance computing (HPC) data center company, announced it inked a 10-year, $3.7 billion deal backed by Alphabet's Google. TeraWulf signs a massive deal for AI data center space Along with releasing its second-quarter earnings, TeraWulf announced a major co-location deal with Fluidstack, an artificial intelligence (AI) cloud provider that will see the company provide 200 megawatts of compute power at its data center in New York. The 10-year, $3.7 billion deal has the option to be extended twice for up to a total of $8.7 billion. Google will guarantee up to $1.8 billion if Fluidstack fails to make good on its lease obligations. In exchange, Google will be awarded warrants for 41 million shares of TeraWulf, about an 8% stake. The guarantee will allow TeraWulf to access the financing it needs to provide the 200 megawatts of compute power. TeraWulf stock is hot, but investors should exercise caution This is the latest major data center deal as big tech races to build enough capacity to meet current and projected future demands. It's hard to overstate just the scale of the efforts. Google, Amazon, Microsoft, and Meta Platforms alone are expected to spend roughly $400 billion next year and are on track to spend more than $350 billion this year. That's not total capital expenditures (capex), that is specifically data center capex. While this presents an enormous opportunity for data center providers, it also presents an enormous risk. I believe that the big tech companies are very purposefully making deals such as this one to offload the risk onto third parties. TeraWulf and other infrastructure companies like it are taking on enormous amounts of debt at very high interest rates. If there is an overbuild or AI demand sags, TeraWulf could find itself in a pretty precarious position. Should you invest $1,000 in TeraWulf right now? Before you buy stock in TeraWulf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TeraWulf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Why TeraWulf Stock Is Skyrocketing Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
